FDA
-
-
-
-
-
-
-
Melinta Therapeutics (MLNT) Reports FDA Approval of Supplemental NDA for BAXDELA (delafloxacin) for Treatment of CABP
-
-
-
-
-
-
-
Melinta Therapeutics Announces Preliminary Second Quarter 2019 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
Melinta Therapeutics Announces Multiple Presentations at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
-
-
-
-
-
-
-
Melinta Therapeutics Reports Third Quarter 2018 Financial Results
-
-
-
-
-
-
-
Melinta Therapeutics Receives Positive CHMP Opinion for Vabomere⢠(meropenem and vaborbactam)
-
-
-
-
-
-
-
Melinta Therapeutics Presents Results from VABOMERE TANGO II Trial at ECCMID 2018, Highlighting Outcomes in Vulnerable Patient Populations
-
-
-
-
-
-
-
Melinta Therapeutics Publishes Complete Results from Phase 3 TANGO I Study of VABOMERE⢠(meropenem and vaborbactam) in Patients with cUTI
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

